Cancer: Role of Nutrition, Pathogenesis, Diagnosis and Management

Ahmed M. Kabel^{1, 2,} and Maaly A. Abd Elmaaboud²

¹Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, Saudi Arabia

²Department of Pharmacology, Faculty of Medicine, Tanta University, Tanta, Egypt

Cite this paper:
Ahmed M. Kabel and Maaly A. Abd Elmaaboud. Cancer: Role of Nutrition, Pathogenesis, Diagnosis and Management. World Journal of Nutrition and Health. 2014; 2(4):48-51. doi: 10.12691/jnh-2-4-1

Abstract

Cancer is characterized by unregulated cell growth. It is one of the most causes of death worldwide. It is attributed to environmental, nutritional and genetic factors. Its clinical presentation varies between local, metastatic and systemic symptoms. Lines of treatment include chemotherapy, radiotherapy and surgical removal.

Keywords:
cancer nutrition pathogenesis diagnosis management

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011): Global cancer statistics. Cancer J Clinic; 61 (2): 69-90.
[2]	Abdel-Rahman MN, Kabel AM (2012): Comparative study between the effect of methotrexate and valproic acid on solid Ehrlich tumour. J Egypt Natl Canc Inst; 24 (4):161-7.
[3]	Anand P, Kunnumakkara AB, Kunnumakara AB, et al. (2008): Cancer is a preventable disease that requires major lifestyle changes. Pharm Res; 25 (9): 2097-116.
[4]	Irigaray P, Newby JA, Clapp R et al. (2007): Lifestyle-related factors and environmental agents causing cancer: an overview. Biomed. Pharmacother; 61 (10): 640-58.
[5]	Sasco AJ, Secretan MB, Straif K (2004): Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung cancer; 45 (2): 3-9.
[6]	Proctor RN (2004): The global smoking epidemic: a history and status report. Clinical lung cancer 5 (6): 371-376.
[7]	Schütze M, Boeing H, Pischon T, Rehm J, Kehoe T et al. (2011): Alcohol attributable burden of incidence of cancer in eight European countries based on results from prospective cohort study. BMJ; 342: 1584.
[8]	Kushi LH, Byers T, Doyle C, et al. (2006): American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin; 56 (5): 254-281.
[9]	Park S, Bae J, Nam BH, Yoo KY (2008): Aetiology of cancer in Asia. Asian Pacif J cancer prevent; 9 (3): 371-380.
[10]	Brenner H, Rothenbacher D, Arndt V (2009): Epidemiology of stomach cancer. Method Mol Biol; 472: 467-77.
[11]	Pagano JS, Blaser M, Buendia MA et al. (2004): Infectious agents and cancer: criteria for a causal relation. Semin. Cancer Biol; 14 (6): 453-71.
[12]	Vassilis S, Rafailidis I, Mourtzoukou G, George P, Falagas E (2010): Chronic bacterial and parasitic infections and cancer: a review. J Infect Develop Count; 4 (5): 267-281.
[13]	Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M (2005): Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet; 366 (9499): 1784-93.
[14]	Roukos DH (2009): Genome-wide association studies: how predictable is a person's cancer risk?. Expert review of anticancer therapy; 9 (4): 389-92.
[15]	Gaeta J F (2000): "Chapter 17: Trauma and Inflammation". In Bast RC, Kufe DW, Pollock RE, et al. Holland-Frei Cancer Medicine (5th ed.). Hamilton, Ontario: B.C. Decker.
[16]	Henderson BE, Bernstein L, Ross RK (2000): "Chapter 13: Hormones and the Etiology of Cancer". In Bast RC, Kufe DW, Pollock RE, et al. Holland-Frei Cancer Medicine (5th ed.). Hamilton, Ontario: B.C. Decker.
[17]	Croce CM (2008): Oncogenes and cancer. New Eng J Med; 358 (5): 502-511.
[18]	Knudson AG (2001): Two genetic hits (more or less) to cancer. Nature reviews. Cancer; 1 (2): 157-62.
[19]	Nelson DA, Tan TT, Rabson AB, Anderson D, Degenhardt K, White E (2004): Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes & Development 18 (17): 2095-107.
[20]	Merlo LM, Pepper JW, Reid BJ, Maley CC (2006): Cancer as an evolutionary and ecological process. Nat Rev Cancer; 6 (12): 924-35.
[21]	Kabel AM, Abdel-Rahman MN, El-Sisi Ael-D, Haleem MS, Ezzat NM, El Rashidy MA (2013). Effect of atorvastatin and methotrexate on solid Ehrlich tumor. Eur J Pharmacol; 713 (1-3): 47-53.
[22]	Larsson SC, Wolk A (2007): Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterol; 132 (5): 1740-5.
[23]	Zheng W, Lee SA (2009): Well-done meat intake, heterocyclic amine exposure, and cancer risk. Nutr Cancer; 61 (4): 437-446.
[24]	Boffetta P, Couto E, Wichmann J, et al. (2010): Fruit and vegetable intake and overall cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst; 8 (102): 529-37.
[25]	Ornish D, Weidner G, Fair WR, Marlin R, Pettengill EB, Raisin CJ, et al. (2005): Intensive lifestyle changes may affect the progression of prostate cancer. J Urol; 174 (3): 1065-1069.
[26]	Chlebowski RT, Blackburn GL, Thomson CA et al. (2006): Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst; 98 (24): 1767-1776.
[27]	Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW (2011): Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377 (9759): 31-41.
[28]	Vogel V, Costantino J, Wickerham D, Cronin W, Cecchini R, et al. (2006): Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295 (23): 2727-2741.
[29]	Thompson I, Goodman P, Tangen C, Lucia M, Miller G, et al. (2003): The influence of finasteride on the development of prostate cancer. N Engl J Med; 349 (3): 215-24.
[30]	Bertagnolli M, Eagle C, Zauber A, Redston M, Solomon S, et al. (2006): Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med; 355 (9): 873-884.
[31]	Wilson JMG, Jungner G (1968): Principles and practice of screening for disease. Geneva: World Health Organization. Public Health Papers; p. 34.
[32]	Gulati AP, Domchek SM (2008): The clinical management of BRCA1 and BRCA2 mutation carriers. Current oncology reports; 10 (1): 47-53.
[33]	Sleigh SH, Barton CL (2010): Repurposing Strategies for Therapeutics. Pharm Med; 24 (3): 151-159.
[34]	Hayden EC (2009): Cutting off cancer's supply lines. Nature; 458 (7239): 686-687.
[35]	Winther H, Jorgensen JT (2010): Drug-Diagnostic Co-Development in Cancer. Pharm Med; 24 (6): 363-375.
[36]	Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, Blumberg JB (2008): Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?. J Natl Cancer Instit; 100 (11): 773-783.
[37]	Brumley R, Enguidanos S, Jamison P, Seitz R, Morgenstern N, Saito S, McIlwane J, Hillary K, Gonzalez J (2007): Increased satisfaction with care and lower costs: results of a randomized trial of in-home palliative care". J Amer Ger Soc; 55 (7): 993-1000.